ARNS Response to NICE Asthma Guidance

ARNS Response to NICE Asthma Guidance
  • In the UK, 5.4 million people are currently receiving treatment for asthma: 1.1 million children (1 in 11) and 4.3 million adults (1 in 12).
  • The UK has amongst the highest prevalence rates for asthma in Europe, according to the European Community Health Survey
  • Tragically, the National Review of Asthma Deaths  found that two thirds of asthma deaths are preventable with good, basic care.

Asthma is a condition which can be hard to diagnose and without a single absolute test to diagnose, research has shown that under diagnosis and under treatment is a problem.

Becky Sherrington, Chair of ARNS, said “I support the NICE recommendations, although I appreciate that the tests aren’t widely available at the moment, so an investment in training and equipment will be needed in both primary and secondary care.  I believe that this guidance supports better diagnosis and personalised asthma care.”

ARNS members are asked to send any comments they wish to make on NICE Guidance to  which may be included in the ARNS’ response by Monday, 2nd February 2015.


Thanks to all our Partner organisations

AstraZeneca Boehringer Chiesi NAPP gsk